• Conditions & Treatments

  • Learn from the Experts

  • Support Your Practice

  • Conferences & Highlights

  • Community Resources

  • Our Expert Network

CME & EducationAbout Us
Loading...
CME & EducationAbout Us
Loading profile...
  • Conditions & Treatments

  • Learn from the Experts

  • Support Your Practice

  • Conferences & Highlights
  • Community Resources

  • Our Expert Network
Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Helpful Links

Terms of Service

Editorial & Medical Review Policy

Privacy Policy

Cookie Policy

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2026 dermsquared | All Rights Reserved

  1. Home
  2. Videos
  3. Discourses In Dermatology
  4. Addressing Thyroid Concerns Vitiligo Patient Centered Perspective

Addressing Thyroid Concerns in Vitiligo: A Patient-Centered Perspective

Featuring:
SDSeemal Desai, MDEducation Advisor
Updated:Aug 21, 2024
VitiligoVitiligo

About this video

When patients with vitiligo ask about the potential link between thyroid issues and their condition, it’s essential for dermatologists to provide clear, accurate, and compassionate guidance. In this episode of Topical Conversations, Dr Seemal Desai emphasizes the importance of framing the conversation around thyroid disease rather than specifically focusing on thyroid cancer. 

Understanding the connection between vitiligo and thyroid disease 

A vitiligo diagnosis often prompts patients to inquire about its association with thyroid cancer. Dr Desai advises that while there is a recognized link between vitiligo and thyroid disease, it’s crucial to clarify that this connection does not necessarily equate to an increased risk of thyroid cancer. Instead, the focus should be on the broader spectrum of thyroid diseases like autoimmune thyroiditis. 

Screening and monitoring: a tailored strategy 

Dr Desai does not advocate for frequent, routine thyroid screening every 3 to 6 months for patients with vitiligo. Instead, he recommends conducting an initial screening at the first visit, including blood work to assess for thyroid function and any signs of autoimmune disease. Subsequent screenings should be based on the patient’s symptoms and overall progression. This individualized approach ensures that patients are not subjected to unnecessary tests while still receiving regular monitoring for potential thyroid issues. 

The patient-centered approach 

Counseling patients with vitiligo about the potential link to thyroid disease requires a balanced, patient-centered approach. By focusing on the broader spectrum of thyroid disease rather than just thyroid cancer, dermatologists can provide comprehensive care that addresses patients’ concerns while promoting long-term health. Dr Desai’s approach underscores the importance of individualized screening and careful monitoring, ensuring that patients receive the right care at the right time.

1
Integrating 31-GEP Testing into SLNB Decision-Making in Cutaneous Melanoma
5:04

Integrating 31-GEP Testing into SLNB Decision-Making in Cutaneous Melanoma

2
What Changes When We Treat Psoriasis as Systemic Disease?
7:01

What Changes When We Treat Psoriasis as Systemic Disease?

3
Who to Look for and When to Act
2:31

Who to Look for and When to Act

4
How Oral TYK2 Inhibition Is Showing Up in Real Decisions
10:38

How Oral TYK2 Inhibition Is Showing Up in Real Decisions

5
Injecting on Bone: A Practical Approach to Filler Safety
0:44

Injecting on Bone: A Practical Approach to Filler Safety

6
Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma: ≥2-Year Follow-Up from the Pivotal Study
8:12

Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma: ≥2-Year Follow-Up from the Pivotal Study

7
Earlier Treatment, Different Outcomes: Secukinumab and the HS Disease Course
2:51

Earlier Treatment, Different Outcomes: Secukinumab and the HS Disease Course

8
Fast Relief, Sustained Control: What Remibrutinib Shows in CSU
2:42

Fast Relief, Sustained Control: What Remibrutinib Shows in CSU

9
Bullous Pemphigoid: The Evolving Treatment Landscape
8:22

Bullous Pemphigoid: The Evolving Treatment Landscape

10
Confirming BP Diagnosis and Choosing Treatment
7:42

Confirming BP Diagnosis and Choosing Treatment

11
How Dermatologists Use Hedgehog Inhibitors for Locally Advanced BCC
4:08

How Dermatologists Use Hedgehog Inhibitors for Locally Advanced BCC

12
What Four Years Can Tell Us About Treating Moderate to Severe HS
3:29

What Four Years Can Tell Us About Treating Moderate to Severe HS

13
Early Response, Sustained Control: 52-Week Outcomes With Remibrutinib
3:18

Early Response, Sustained Control: 52-Week Outcomes With Remibrutinib

14
A Review of Dermoscopy Techniques With Michelle Tarbox, MD
1:28

A Review of Dermoscopy Techniques With Michelle Tarbox, MD

15
Leading With Intention in Aesthetic Assessment
2:57

Leading With Intention in Aesthetic Assessment

16
Recognizing Bullous Pemphigoid Earlier in Clinical Practice
1:52

Recognizing Bullous Pemphigoid Earlier in Clinical Practice

17
Tildrakizumab in Psoriasis: Adherence, Persistence, and the Role of In-Office Administration
10:34

Tildrakizumab in Psoriasis: Adherence, Persistence, and the Role of In-Office Administration

18
Advancing Bullous Pemphigoid Care: Clinical Insights From Dr. Del Rosso
23:00

Advancing Bullous Pemphigoid Care: Clinical Insights From Dr. Del Rosso

19
Strengthening Confidence in Hedgehog Inhibitors for Locally Advanced Basal Cell Carcinoma
8:33

Strengthening Confidence in Hedgehog Inhibitors for Locally Advanced Basal Cell Carcinoma

20
Advancing Melanoma Prognostics: Clinical Evidence Supporting the 31-GEP Test
6:53

Advancing Melanoma Prognostics: Clinical Evidence Supporting the 31-GEP Test

21
Topical Truths: Managing AD in the Real World
21:54

Topical Truths: Managing AD in the Real World

22
The Oral Conversation: How We Talk to Patients About Systemic Therapy Today
30:51

The Oral Conversation: How We Talk to Patients About Systemic Therapy Today

23
Part 4: How Dermatologists Approach SI/B Warnings in Daily Practice
10:00

Part 4: How Dermatologists Approach SI/B Warnings in Daily Practice

24
Part 1: Psoriasis and Mental Health: Understanding Depression and Suicidality Risk
10:04

Part 1: Psoriasis and Mental Health: Understanding Depression and Suicidality Risk

25
Part 2: Psoriasis and Mental Health: The Inflammatory and Biochemical Pathways
9:36

Part 2: Psoriasis and Mental Health: The Inflammatory and Biochemical Pathways

26
Part 3: Psoriasis and Mental Health: How to Navigate SI/B Warnings With Patients
9:51

Part 3: Psoriasis and Mental Health: How to Navigate SI/B Warnings With Patients

27
Fall Clinical Continuity Experience - Vtama - Lecture Recap Video
0:35

Fall Clinical Continuity Experience - Vtama - Lecture Recap Video

28
Four Years of Data: Durability and Distinction with TYK2 Inhibition
3:09

Four Years of Data: Durability and Distinction with TYK2 Inhibition

29
What an Oral Option Means for Psoriasis Care
2:34

What an Oral Option Means for Psoriasis Care

30
LAUNCH ALERT: FDA Approves Anzupgo (Delgocitinib) Cream for Moderate-to-Severe Chronic Hand Eczema in Adults
8:39

LAUNCH ALERT: FDA Approves Anzupgo (Delgocitinib) Cream for Moderate-to-Severe Chronic Hand Eczema in Adults

31
Bimzelx in Focus: Versatile Care for Enhanced Dermatologic Outcomes
7:58

Bimzelx in Focus: Versatile Care for Enhanced Dermatologic Outcomes

32
Discover VTAMA: A Next-Generation Treatment for Plaque Psoriasis
4:59

Discover VTAMA: A Next-Generation Treatment for Plaque Psoriasis

33
VTAMA: A New Standard in Psoriasis Management
4:59

VTAMA: A New Standard in Psoriasis Management

34
Exploring the MyPath Melanoma Test for Guiding Management and Care Decisions in Patients with Ambiguous Lesions
18:17

Exploring the MyPath Melanoma Test for Guiding Management and Care Decisions in Patients with Ambiguous Lesions

35
Bimekizumab for Plaque Psoriasis: Its Impact in Clinical Practice
16:27

Bimekizumab for Plaque Psoriasis: Its Impact in Clinical Practice

36
Bimekizumab for Plaque Psoriasis: Insights into Efficacy, Safety, and Dosing
6:45

Bimekizumab for Plaque Psoriasis: Insights into Efficacy, Safety, and Dosing

37
Psoriasis mechanism of disease: Pathogenesis
8:27

Psoriasis mechanism of disease: Pathogenesis

38
Psoriasis mechanism of disease: Genetic, environmental, and lifestyle factors
12:45

Psoriasis mechanism of disease: Genetic, environmental, and lifestyle factors